NEWS HIGHLIGHTS
Published Studies Related to Idamycin (Idarubicin)
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. [2007.10]
BACKGROUND AND OBJECTIVES: Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation... CONCLUSIONS: Adding lomustine to induction with idarubicin and cytarabine therapy did not statistically improve survival in elderly patients with AML. Adding intermediate-dose cytarabine to consolidation therapy did not improve outcome.
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. [2006.11]
Two hundred untreated patients with low grade NHL (KIEL), including 155 follicular NHL, were randomized to six courses of treatment with chlorambucil 20 mg m-2 for 3 days and dexamethasone 4 mg bd for 5 days (CD) vs the same regimen plus oral idarubicin 10 mg m-2 for 3 days (CID)... CID is a potential for combination with antibody therapy particularly in older patient groups.
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. [2005.10]
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients <60 years.
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. [2005.08]
We conducted a randomised trial comparing an intensified versus a standard conditioning regimen for high-dose chemotherapy followed by autologous stem-cell transplantation in patients with multiple myeloma. In this study, 56 patients were randomly assigned for high-dose therapy with melphalan 200 mg/m2 or with idarubicin 42 mg/m2, melphalan 200 mg/m2 and cyclophosphamide 120 mg/kg...
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. [2005.06]
A higher complete remission (CR) rate was observed in patients with acute myeloid leukemia (AML) who, on a prior randomized study of induction therapy, received gemtuzumab ozogamicin (GO) plus interleukin-11 (IL-11) rather than GO alone. An adaptive randomized phase III study of the addition of IL-11 to idarubicin and cytarabine (IA) induction in 100 patients >/=50 years of age with AML or high-risk myelodysplastic syndrome (MDS) was conducted...
Clinical Trials Related to Idamycin (Idarubicin)
Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML [Recruiting]
The goal of this clinical research study is to find the best safe dose for 2 different drug
combinations. For this purpose, participants will either receive the combination of
clofarabine plus idarubicin or clofarabine plus idarubicin and ara-C. Once the best safe
dose for these drug combinations are found, the next goal is to compare the drug
combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in
the treatment of patients with AML, high-grade MDS, or myeloid blast phase of CML who have
relapsed following their initial therapy. In the current extension part of the study, you
will only receive the clofarabine/idarubicin/ara-C combination. The activity and the safety
of this treatment will be studied.
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML [Recruiting]
The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and
idarubicin given in combination to newly diagnosed AML patients >60 years or relapsed AML
patients.
Another purpose of this study is to determine the dose limiting toxicities associated with
bortezomib in combination with idarubicin in newly diagnosed AML patients >60 years or
relapsed AML patients.
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Completed]
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different
ways to stop cancer cells from dividing so they stop growing or die. Bevacizumab may stop the
growth of cancer by stopping blood flow to the leukemic cells in the bone marrow. Giving
idarubicin and cytarabine with bevacizumab may kill more cancer cells. It is not yet know
whether giving idarubicin together with cytarabine is more effective with or without
bevacizumab in treating acute myeloid leukemia.
PURPOSE: This randomized phase II trial is studying how well giving idarubicin and cytarabine
together with bevacizumab works compared to idarubicin and cytarabine alone in treating
patients with newly diagnosed acute myeloid leukemia.
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML [Completed]
The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625)
to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used
alone or in combination with Cytarabine (Ara-C).
Cenersen sodium is a drug that is designed to block the effects of a protein called p53.
Laboratory evidence shows that blocking p53 will make many types of cancer, including acute
myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics
while making normal tissues more resistant to the toxic effects of these agents.
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) [Recruiting]
A primary goal of this clinical research study is to find the highest safe dose of sorafenib
that can be given in combination with idarubicin and Ara-C for the treatment of acute
myelogenous leukemia (AML) and high-risk, myelodysplastic syndrome (MDS).
Once the highest safe dose is found, researchers will then try to learn if this combination
treatment can help control AML and high-risk MDS in newly diagnosed patients. The safety of
this treatment combination will also be studied.
|
